로딩 중…
지수 로딩 중…
Keros Therapeutics, Inc.
KROS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$10.11+0.40%
2026-08-03
Financials
Valuation Metrics
Keros Therapeutics, Inc.'s Market Cap is $200M. At end of 2025 it was $758M. Ranked #3031 of 3,112 in US market (top 97%), #1378 of 1,445 on NASDAQ (top 95%), #253 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $200M | US#3,031/3,112 Sec#253/269 |
| Revenue | $33M | US#2,887/3,112 Sec#166/269 |
| Net Income | $-85M | US—/3,112 Sec—/269 |
| Total Assets | $312M | US#2,885/3,112 Sec#206/269 |
| Net Assets | $286M | US#2,573/3,112 Sec#162/269 |
| Value | ||
| P/B | 0.70x | US#141/3,112 Sec#4/269 |
| P/S | 6.03x | US#2,388/3,112 Sec#95/269 |
| FCF Yield | -29.11% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -29.81% | US#2,613/3,112 Sec#126/269 |
| ROA | -27.26% | US#2,849/3,112 Sec#153/269 |
| Op. Margin | -332.55% | US#2,881/3,112 Sec#153/269 |
| Revenue Growth | -99.83% | US#2,946/3,112 Sec#189/269 |
| Earnings Growth | -115.97% | US#2,116/3,112 Sec#68/269 |
| Financial Health | ||
| Debt Ratio | 9.33% | US#98/3,112 Sec#42/269 |
| Total Debt | $16M | US#2,729/3,112 Sec#188/269 |
| FCF | $-58M | US#2,487/3,112 Sec#118/269 |
| Cash | $281M | US#1,478/3,112 Sec#87/269 |
| Current Ratio | 22.62x | US#110/3,112 Sec#23/269 |
| Performance | ||
| 1Y Return | -29.40% | US#2,766/3,112 Sec#226/269 |
| 1M Return | -10.21% | US#2,605/3,112 Sec#165/269 |
| From 52W High | -55.17% | US#2,864/3,112 Sec#230/269 |
| 1Y MDD | -54.62% | US#2,561/3,112 Sec#199/269 |
| Trading | ||
| Volume | 153,418 shares | US#2,782/3,112 Sec#257/269 |
| Trading Value | $2M | US#2,977/3,112 Sec#250/269 |
| Per Share | ||
| EPS | $2.34 | US#1,158/3,112 Sec#37/269 |
| BPS | $8.14 | US#1,922/3,112 Sec#81/269 |